
KRYS
Healthcare · Biotechnology · $9.05B market cap
$305.23-0.45 (-0.1%)Nov 13, 4:26 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +3.4% over 90 days · 30-day revisions 1 up, 2 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 2, 2026 | Before the open | 1.84 | 2.05 | +11.4% |
| Aug 3, 2026 | Before the open | 1.70 | 1.79 | +5.3% |
| May 4, 2026 | Before the open | 1.42 | 1.83 | +28.9% |
| Feb 17, 2026 | Time not confirmed | 1.58 | 1.70 | +7.6% |
| Nov 3, 2025 | Before the open | 1.12 | 2.66 | +137.5% |
| Aug 4, 2025 | Before the open | 1.44 | 1.29 | -10.4% |
| May 6, 2025 | Before the open | 1.52 | 1.20 | -21.1% |
| Feb 24, 2025 | Before the open | 1.85 | 1.53 | -17.4% |
| Nov 4, 2024 | Before the open | 0.90 | 0.91 | +1.1% |
| Aug 5, 2024 | Before the open | 0.99 | 0.93 | -6.1% |
| May 6, 2024 | Before the open | 0.15 | 0.03 | -80.0% |
| Feb 26, 2024 | Before the open | -0.25 | 0.96 | +484.0% |
| Nov 6, 2023 | Before the open | -0.67 | -0.67 |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis…
| 0.0% |
| Aug 7, 2023 | Before the open | -0.74 | -1.25 | -68.9% |
| May 8, 2023 | Before the open | -1.44 | -1.76 | -22.2% |
| Feb 27, 2023 | Before the open | -0.56 | -1.25 | -123.2% |
| Nov 7, 2022 | Before the open | -1.26 | -1.17 | +7.1% |
| Aug 8, 2022 | Before the open | -1.00 | -1.10 | -10.0% |
| May 9, 2022 | After the close | -1.05 | -0.99 | +5.7% |
| Feb 28, 2022 | Before the open | -0.73 | -0.95 | -30.1% |
| Nov 8, 2021 | Before the open | -0.74 | -0.70 | +5.4% |
| Aug 9, 2021 | Before the open | -0.78 | -0.74 | +5.1% |
| May 10, 2021 | Before the open | -0.56 | -0.74 | -32.1% |
| Mar 1, 2021 | Before the open | -0.59 | -0.53 | +10.2% |
| Nov 9, 2020 | Before the open | -0.46 | -0.49 | -6.5% |
| Aug 10, 2020 | Before the open | -0.39 | -0.37 | +5.1% |
| May 4, 2020 | Before the open | -0.44 | -0.31 | +29.5% |
| Mar 10, 2020 | Before the open | -0.33 | -0.31 | +6.1% |
| Nov 4, 2019 | Before the open | -0.40 | -0.25 | +37.5% |
| Aug 5, 2019 | Before the open | -0.31 | -0.37 | -19.4% |
| May 6, 2019 | Before the open | -0.33 | -0.29 | +12.1% |
| Mar 12, 2019 | Before the open | -0.23 | -0.27 | -17.4% |
| Nov 5, 2018 | Before the open | -0.26 | -0.26 | 0.0% |
| Aug 6, 2018 | Before the open | -0.34 | -0.22 | +35.3% |
| May 7, 2018 | Before the open | -0.48 | -0.21 | +56.3% |
| Mar 12, 2018 | After the close | -0.23 | -0.26 | -13.0% |